Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis
- PMID: 30177784
- DOI: 10.1038/s41395-018-0222-5
Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis
Abstract
Objectives: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder that is thought to be due to a disorder of brain-gut function. Drugs acting centrally, such as antidepressants, and psychological therapies may, therefore, be effective.
Methods: We updated a previous systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE, EMBASE, PsychINFO, and the Cochrane Controlled Trials Register were searched (up to July 2017). Trials recruiting adults with IBS, which compared antidepressants versus placebo, or psychological therapies versus control therapy or "usual management" were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI).
Results: The search strategy identified 5316 citations. Fifty-three RCTs, reported in 51 separate articles, were eligible for inclusion: 17 compared antidepressants with placebo, 35 compared psychological therapies with control therapy or "usual management", and one compared both psychological therapy and antidepressants with placebo. Four of the trials of psychological therapies, and one of the RCTs of antidepressants, were identified since our previous meta-analysis. The RR of IBS symptoms not improving with antidepressants versus placebo was 0.66 (95% CI 0.57-0.76), with similar treatment effects for both tricyclic antidepressants and SSRIs, although with heterogeneity between RCTs of the latter (I(2) = 49%, P = 0.07). The RR of symptoms not improving with psychological therapies was 0.69 (95% CI 0.62-0.76). Cognitive behavioral therapy, relaxation therapy, multi-component psychological therapy, hypnotherapy, and dynamic psychotherapy were all beneficial when data from two or more RCTs were pooled. There was significant heterogeneity between studies (I(2) = 69%, P < 0.001) and significant funnel plot asymmetry. There were also issues regarding trial design, including lack of blinding.
Conclusions: Antidepressants are efficacious in reducing symptoms in IBS patients. Psychological therapies also appear to be effective treatments for IBS, although there are limitations in the quality of the evidence, and treatment effects may be overestimated as a result.
Similar articles
-
Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.Am J Gastroenterol. 2014 Sep;109(9):1350-65; quiz 1366. doi: 10.1038/ajg.2014.148. Epub 2014 Jun 17. Am J Gastroenterol. 2014. PMID: 24935275 Review.
-
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.Gut. 2009 Mar;58(3):367-78. doi: 10.1136/gut.2008.163162. Epub 2008 Nov 10. Gut. 2009. PMID: 19001059 Review.
-
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis.Gut. 2020 Aug;69(8):1441-1451. doi: 10.1136/gutjnl-2020-321191. Epub 2020 Apr 10. Gut. 2020. PMID: 32276950
-
Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2020 Feb;5(2):117-131. doi: 10.1016/S2468-1253(19)30324-3. Epub 2019 Dec 16. Lancet Gastroenterol Hepatol. 2020. PMID: 31859183
-
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD003460. doi: 10.1002/14651858.CD003460.pub3. Cochrane Database Syst Rev. 2011. PMID: 21833945 Free PMC article. Review.
Cited by
-
Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians.Dig Dis Sci. 2024 Dec;69(12):4336-4346. doi: 10.1007/s10620-024-08716-y. Epub 2024 Nov 13. Dig Dis Sci. 2024. PMID: 39537891 Review.
-
Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options.Microorganisms. 2024 Oct 9;12(10):2036. doi: 10.3390/microorganisms12102036. Microorganisms. 2024. PMID: 39458345 Free PMC article. Review.
-
Clinicians' Knowledge, Attitudes, and Practices Regarding the Management of Functional Gastrointestinal Disorders With Neuromodulators and Psychological Treatment.J Neurogastroenterol Motil. 2024 Oct 30;30(4):480-490. doi: 10.5056/jnm23161. J Neurogastroenterol Motil. 2024. PMID: 39397625 Free PMC article.
-
Clinicians' Knowledge, Attitudes, and Practices Towards Neuromodulators and Psychological Treatment in Functional Gastrointestinal Disorders - Do They Know?J Neurogastroenterol Motil. 2024 Oct 30;30(4):385-386. doi: 10.5056/jnm24125. J Neurogastroenterol Motil. 2024. PMID: 39397616 Free PMC article. No abstract available.
-
Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.Health Technol Assess. 2024 Oct;28(66):1-161. doi: 10.3310/BFCR7986. Health Technol Assess. 2024. PMID: 39397570 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
